MedTrace Logo

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

NCT02429193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-01-13

No results posted yet for this study

Summary

This is an open-label phase 2 multi-center study of abiraterone and enzalutamide in men with castration-resistant prostate cancer. Sixteen patients will be enrolled over 18 months.

Conditions

  • Castration-resistant Prostate Cancer

Interventions

DRUG

Abiraterone + prednisone

Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)

DRUG

Enzalutamide

Enzalutamide (160 mg/day p.o.)

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Anthony Joshua, MD,MBBS,PhD,FRACP · University Health Network, Toronto

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-09-01
Completion
2019-09-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02429193 on ClinicalTrials.gov